Perspective Therapeutics (CATX) EBT (2010 - 2026)

Perspective Therapeutics has disclosed EBT across 17 years of filings, most recently posting -$26.2 million for Q1 2026.

• EBT for Q1 2026 came in at -$26.2 million, down 44.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$8.0 million (up 90.72% YoY), and the FY2024 annual result was -$80.0 million, down 99.44% from the prior year.
• EBT came in at -$26.2 million for Q1 2026 at Perspective Therapeutics, down from $66.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of $66.1 million in Q4 2025 to a low of -$41.8 million in Q4 2024.
• The 5-year median for EBT is -$11.1 million (2023), against an average of -$9.5 million.
• Across the five-year window, EBT tumbled 707.05% in 2023 and jumped 258.14% in 2025, its largest moves.
• Perspective Therapeutics' EBT stood at -$7.3 million in 2022, then declined by 5.97% to -$7.8 million in 2023, then sank by 438.12% to -$41.8 million in 2024, then surged by 258.14% to $66.1 million in 2025, then tumbled by 139.59% to -$26.2 million in 2026.
• The last three EBT figures came in at -$26.2 million (Q1 2026), $66.1 million (Q4 2025), and -$26.0 million (Q3 2025), per Business Quant data.